Infinity PhII results a blow for PI3K in inflammation
This article was originally published in Scrip
Executive Summary
Infinity Pharmaceuticals has discontinued development of its oral PI3K inhibitor duvelisib in rheumatoid arthritis after the candidate failed in a Phase II trial.
You may also be interested in...
Infinity Doesn't Sugarcoat Disappointing Duvelisib Data; Cuts R&D Staff To Preserve Cash
Infinity's hopes for accelerated approval of duvelisib based on the DYNAMO study have been dashed, so as the company plots a new strategy for the PI3K inhibitor – with or without its partner AbbVie – it has cut discovery research operations, including 46 jobs.
Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again
Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.